The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis
ConclusionsGATM polymorphism including rs9806699 G>A, rs1719247 C>T, and rs1346268 T>C may be protective factors of SIM.GATM rs9806699 G>A may only exert protective effect on mild SIM cases. Our meta-analysis indicates thatGATM polymorphism may represent a pharmacogenomics biomarker for predicting incidence of SIM, which contributes to risk stratification and optimizing statin adherence.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cholesterol | Databases & Libraries | Drugs & Pharmacology | Genetics | Niacin | Niaspan | Science | Statin Therapy | Study | Vitamin B3